Arcoma AB (ARCOMA) - Net Assets

Latest as of September 2025: Skr73.39 Million SEK ≈ $7.90 Million USD

Based on the latest financial reports, Arcoma AB (ARCOMA) has net assets worth Skr73.39 Million SEK (≈ $7.90 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr97.97 Million ≈ $10.54 Million USD) and total liabilities (Skr24.58 Million ≈ $2.64 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Arcoma AB to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr73.39 Million
% of Total Assets	74.91%
Annual Growth Rate	7.78%
5-Year Change	19.79%
10-Year Change	18.87%
Growth Volatility	67.35

Arcoma AB - Net Assets Trend (2012–2024)

This chart illustrates how Arcoma AB's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Arcoma AB for the complete picture of this company's asset base.

Annual Net Assets for Arcoma AB (2012–2024)

The table below shows the annual net assets of Arcoma AB from 2012 to 2024. For live valuation and market cap data, see ARCOMA company net worth.

Year	Net Assets	Change
2024-12-31	Skr59.33 Million ≈ $6.39 Million	+21.94%
2023-12-31	Skr48.66 Million ≈ $5.24 Million	+6.06%
2022-12-31	Skr45.88 Million ≈ $4.94 Million	+4.17%
2021-12-31	Skr44.04 Million ≈ $4.74 Million	-11.09%
2020-12-31	Skr49.53 Million ≈ $5.33 Million	+9.62%
2019-12-31	Skr45.19 Million ≈ $4.86 Million	+15.76%
2018-12-31	Skr39.03 Million ≈ $4.20 Million	-4.41%
2017-12-31	Skr40.83 Million ≈ $4.39 Million	+9.33%
2016-12-31	Skr37.35 Million ≈ $4.02 Million	-25.18%
2015-12-31	Skr49.92 Million ≈ $5.37 Million	+19.62%
2014-12-31	Skr41.73 Million ≈ $4.49 Million	+233.32%
2013-12-31	Skr12.52 Million ≈ $1.35 Million	-48.15%
2012-12-31	Skr24.14 Million ≈ $2.60 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Arcoma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 116.9% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	Skr32.96 Million	55.55%
Common Stock	Skr26.37 Million	44.45%
Other Comprehensive Income	Skr29.22 Million	49.24%
Total Equity	Skr59.33 Million	100.00%

Arcoma AB Competitors by Market Cap

The table below lists competitors of Arcoma AB ranked by their market capitalization.

Company	Market Cap
Clinical Laserthermia Systems AB (publ) ST:CLS-B	$11.57 Million
The Grob Tea Company Limited NSE:GROBTEA	$11.58 Million
Telecom Plus PLC LSE:TEP	$11.58 Million
Holand og Setskog Sparebank OL:HSPG	$11.58 Million
Yelooo Integra Datanet Tbk PT JK:YELO	$11.54 Million
iOThree Limited Ordinary Shares NASDAQ:IOTR	$11.54 Million
Cielo Waste Solutions Corp V:CMC	$11.53 Million
Media Investment Optimization SL MC:MIO	$11.52 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Arcoma AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 48,657,000 to 59,334,000, a change of 10,677,000 (21.9%).
Net income of 11,179,000 contributed positively to equity growth.
Other comprehensive income increased equity by 10,677,001.
Other factors decreased equity by 11,179,001.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	Skr11.18 Million	+18.84%
Other Comprehensive Income	Skr10.68 Million	+17.99%
Other Changes	Skr-11.18 Million	-18.84%
Total Change	Skr-	21.94%

Book Value vs Market Value Analysis

This analysis compares Arcoma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.67x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 26.93x to 1.67x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2012-12-31	Skr0.28	Skr7.50	x
2013-12-31	Skr0.14	Skr7.50	x
2014-12-31	Skr0.86	Skr7.50	x
2015-12-31	Skr4.80	Skr7.50	x
2016-12-31	Skr3.61	Skr7.50	x
2017-12-31	Skr3.50	Skr7.50	x
2018-12-31	Skr3.09	Skr7.50	x
2019-12-31	Skr3.57	Skr7.50	x
2020-12-31	Skr3.89	Skr7.50	x
2021-12-31	Skr3.40	Skr7.50	x
2022-12-31	Skr3.51	Skr7.50	x
2023-12-31	Skr3.65	Skr7.50	x
2024-12-31	Skr4.50	Skr7.50	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Arcoma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 18.84%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 7.13%
• Asset Turnover: 1.95x
• Equity Multiplier: 1.36x
Recent ROE (18.84%) is above the historical average (-11.35%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2012	-13.36%	-2.19%	2.16x	2.84x	Skr-5.64 Million
2013	-92.85%	-11.47%	1.43x	5.66x	Skr-12.88 Million
2014	2.19%	0.70%	1.65x	1.90x	Skr-3.26 Million
2015	-12.92%	-5.23%	1.46x	1.69x	Skr-11.44 Million
2016	-31.18%	-11.41%	1.43x	1.91x	Skr-15.38 Million
2017	-24.05%	-10.69%	1.35x	1.67x	Skr-13.90 Million
2018	-4.06%	-1.33%	1.57x	1.95x	Skr-5.49 Million
2019	14.63%	4.94%	1.60x	1.84x	Skr2.09 Million
2020	2.76%	1.16%	1.24x	1.92x	Skr-3.59 Million
2021	-16.97%	-6.38%	1.48x	1.80x	Skr-11.88 Million
2022	4.15%	1.52%	1.25x	2.19x	Skr-2.69 Million
2023	5.27%	1.57%	1.99x	1.68x	Skr-2.30 Million
2024	18.84%	7.13%	1.95x	1.36x	Skr5.25 Million

Industry Comparison

This section compares Arcoma AB's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $451,654,384
Average return on equity (ROE) among peers: -71.30%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Arcoma AB (ARCOMA)	Skr73.39 Million	-13.36%	0.33x	$11.55 Million
Acarix A/S (ACARIX)	$76.60 Million	-60.65%	0.08x	$33.84 Million
Bactiguard Holding AB (publ) (BACTI-B)	$353.18 Million	-39.18%	0.87x	$61.64 Million
BICO Group AB (BICO)	$3.01 Billion	-0.18%	0.82x	$159.82 Million
Boule Diagnostics AB (BOUL)	$119.08 Million	0.00%	0.39x	$14.38 Million
CellaVision AB (CEVI)	$429.62 Million	20.83%	0.55x	$311.10 Million
Clinical Laserthermia Systems AB (publ) (CLS-B)	$19.46 Million	-85.28%	0.14x	$11.57 Million
Chordate Medical Holding AB (CMH)	$18.24 Million	-128.06%	0.60x	$29.05K
C-Rad AB (publ) (CRAD-B)	$35.05 Million	-30.59%	0.38x	$86.08 Million
Duearity AB (DEAR)	$6.06 Million	-318.56%	0.99x	$331.97K

About Arcoma AB

ST:ARCOMA Sweden Medical Devices

Market Cap

$11.55 Million

Skr107.31 Million SEK

Market Cap Rank

#26507 Global

#571 in Sweden

Share Price

Skr7.50

Change (1 day)

+0.00%

52-Week Range

Skr6.92 - Skr10.75

All Time High

Skr25.60